Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
08:26:55 EDT Wed 07 Oct 2026
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

C:RVV - Revive Therapeutics Ltd. - https://www.revivethera.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
RVV - C  120.00.025·0.03509.30.03    0.08  0.005Oct 06Sep 1515 min RT 2¢
CSE - C120.00.025·0.03509.30.03    0.08  0.005Oct 0615 min

Recent Trades - All 0 today
Time ETExPriceChangeVolumeBuyerSellerMarkers
        
        
        
        
        
        
        
        
        
        

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolPriceTypeHeadline
2026-09-15 21:12C:RVV0.02News ReleaseRevive sets out plans for bucillamine
2026-08-19 18:47C:RVV0.025News ReleaseRevive Therapeutics arranges $61K shares for debt deal
2026-08-19 17:32C:RVV0.025News ReleaseRevive Therapeutics pushes ahead with bucillamine
2026-08-14 20:36C:RVV0.03News ReleaseRevive Therapeutics grants options to buy 15.5M shares
2026-08-12 17:02C:RVV0.035News ReleaseRevive notes bucillamine, anti-oxidant study
2026-07-16 04:24C:RVV0.03News ReleaseRevive closes $246,920 first tranche of placement
2026-06-26 17:50C:RVV0.03News ReleaseRevive Therapeutics arranges $1-million financing
2026-06-08 13:23C:RVV0.03News Release/C O R R E C T I O N -- Canadian Investment Regulatory Organization (CIRO) - Halts/Resumptions/
2026-06-08 08:45C:RVV0.03News ReleaseCanadian Investment Regulatory Organization Trade Resumption - RVV
2026-06-08 08:04C:RVV0.03News ReleaseCanadian Investment Regulatory Organization Trading Halt - RVV
2026-06-01 21:53C:RVV0.035SEDAR Interim MD & ASEDAR Interim MD & A
2026-06-01 21:52C:RVV0.035SEDAR Interim Financial StatementsSEDAR Interim Financial Statements
2026-05-20 17:06C:RVV0.04News ReleaseRevive expands bucillamine defence program focus
2026-03-11 17:34C:RVV0.04News ReleaseRevive Therapeutics advances bucillamine patents
2026-02-27 19:20C:RVV0.01SEDAR Interim MD & ASEDAR Interim MD & A
2026-02-27 18:58C:RVV0.01SEDAR Interim Financial StatementsSEDAR Interim Financial Statements
2025-12-15 17:09C:RVV0.015News ReleaseRevive Therapeutics primes the pump on Bucillamine
2025-11-28 17:31C:RVV0.01SEDAR Interim MD & ASEDAR Interim MD & A
2025-11-28 17:24C:RVV0.01SEDAR Interim Financial StatementsSEDAR Interim Financial Statements
2025-11-21 16:56C:RVV0.01News ReleaseRevive talks DRDC study on bucillamine for nerve agents